Please assess the completion status of the following clinical trial:

Trial Title: Impact of Nuedexta on Bulbar Physiology and Function in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable-definite ALS (El-Escorial Criterion);~* ALSFRS-R Bulbar subscale score \<10~* Bamboo oral reading speaking rate \<140 words per minute~* No allergies to barium sulfate.~Exclusion Criteria:~* Treatment for sialorrhea within the past 3 months that includes either Botox or radiation treatment~* Participation in another disease modifying study targeting bulbar or cough function~* Use of invasive mechanical ventilation/presence of tracheostomy~* Advanced frontotemporal dementia or significant cognitive dysfunction~* Nil per oral status for feeding (i.e., NPO, nothing by mouth)~* Previously prescribed Nuedexta. Additionally, if participants are taking Riluzole or other medications to control sialorrhea, they must be on a stable dose for at least 30 days prior to enrollment in the current study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- ALS individuals with bulbar dysfunction (Type: EXPERIMENTAL): Participants enrolled in this group will be prescribed dextromethorphan HBr and quinidine sulfate (Nuedexta) as recommended by their treating neurologist. 20 mg dextromethorphan HBr and 10mg quinidine sulfate will be administered orally with 1 capsule every day for the initial 7 days followed by 1 capsule every 12 hours for the remaining 23 days of the study. Participants will be evaluated 30 days apart to determine the impact of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).